Are we ready to replace dimercaprol (BAL) as an arsenic antidote?

Human and Experimental Toxicology

Volumn 16, Issue 8, 1997, Pages 460-465

  Mückter, Harald ^a   Liebl, Bernhard ^a   Reichl, Franz Xaver ^a   Hunder, Göran ^a   Walther, Udo ^a   Fichtl, Burckhard ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antidotes; Arsenicals; Cell culture; In vitro models; Perfused organs; Therapy

Indexed keywords

ANTIDOTE; ARSENIC; DIMERCAPROL; SUCCIMER; UNITHIOL;

ARTICLE; DOG; DRUG EFFICACY; HUMAN; HYDROPHILICITY; INTOXICATION; INTRAMUSCULAR DRUG ADMINISTRATION; JEJUNUM; KIDNEY; NONHUMAN; ODOR; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

CANIS FAMILIARIS; CAVIA;

EID: 0030770326     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1177/096032719701600807     Document Type: Article

References (22)

1. Peters RA, Stocken LA, Thompson RHS. British Anti-Lewisite (BAL). Nature 1945; 156: 616-619.
2. Oehme FW. British anti-lewisite (BAL), the classic heavy metal antidote. Clin Toxicol 1972; 5: 215-222.
3. Aposhian HV et al. DMSA, DMPS, and DMPA - as arsenic antidotes. Fund Appl Toxicol 1984; 4 (Suppl.): S58-S70.
4. Cullen NM, Wolf LR, Clair DS. Pediatric arsenic ingestion. Am J Emerg Med 1995; 13: 432-435.
5. Fournier L et al. 2,3-Dimercaptosuccinic acid treatment of heavy metal poisoning in humans. Med Toxicol Adverse Drug Exp 1988; 3: 499-504.
6. Hruby K, Donner A. 2,3-Dimercapto-1-propanesulphonate in heavy metal poisoning. Med Toxicol Adverse Drug Exp 1987; 2: 317-323.
7. Aposhian HV et al. Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology 1995; 97: 23-38.
8. Dart RC et al. Pharmacokinetics of meso-2,3-dimercaptosuccinic acid in patients with lead poisoning and in healthy adults. J Pediatr 1994; 125: 309-316.
9. O'Connor RJ, McGown EL, Dill K, Hallowell SF. Relative binding constants of arsenical-antidote adducts determined by NMR spectroscopy. Res Commun Chem Pathol Pharmacol 1990; 69: 365-368.
10. 3 poisoning in mice. Arch Toxicol 1990; 64: 387-392.
11. IARC (ed). Some metals and metallic compounds. In: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, IARC (ed). International Agency for Research on Cancer, Lyon (F), vol. 23, pp39-141, 1980.
12. Goldman M, Dacre JC. Inorganic arsenic compounds: are they carcinogenic, mutagenic, teratogenic? Environ Geochem Health 1991; 13: 179-191.
13. Abernathy CO et al. Is ingested inorganic arsenic a 'threshold' carcinogen? Fund Appl Toxicol 1996; 29: 168-175.
14. Hotta N, Asia Arsenic Network (AAN), in AAN Newsletter, Vol 1, Sept 1996. Email: Noboyuki Hotta, GCA01173@nifty.or.jp.
15. 3. Arch Toxicol 1994; 69: 35-39.
16. McRoberts JA, Taub M, Saier MH. The Madin Darby canine kidney (MDCK) cell line. In: Functionally Differentiated Cell Lines. Sato G (ed). Alan R. Liss, Inc., New York, pp 117-139, 1981.
17. Liebl B et al. Influence of glucose on the toxicity of oxophenylarsine in MDCK cells. Arch Toxicol 1995; 69: 421-424.
18. 3. Vet Hum Toxicol 1990; 32: 223-226.
19. Brown SM, Goldstein JL. Drugs used in the treatment of hyperlipoproteinemias. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics. Gilman AG, Rail TW, Nies AS, Taylor P (eds). Pergamon Press, New York - Oxford - Beijing - Frankfurt - São Paulo - Sydney - Tokyo - Toronto, 8th edn, pp 874-896, 1990.
20. 3. Arch Toxicol 1995; 69: 712-717.
21. Hunder G, Nguyen PT, Schümann K, Fichtl B. Influence of inorganic and organic arsenicals on intestinal transfer of nutrients. Res Commun Chem Pathol Pharmacol 1993; 80: 83-92.
22. Fisher RB, Parsons DS. A preparation of surviving rat small intestine for the study of absorption. J Physiol 1949; 110: 3646.